Key facts
- Nuritas’s last known valuation is $384.9M (Nov 2021).
- It has raised $149.7M; the latest was Accelerator/Incubator in Jul 2025.
- Notable investors include Enterprise Ireland, Keiretsu Forum, Builders VC, SVG Ventures|THRIVE, NDRC — 29 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for Nuritas
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuritas are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuritas
Developer of a biotechnology platform designed to extract peptides from food sources. The company's platform combines artificial intelligence and genomics to discover and unlock natural bioactive peptides with health benefits, enabling businesses to make the food system more sustainable by replacing unwanted ingredients and molecules with more natural and sustainable ones.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2014
- Employees
- 60
- Website
- nuritas.com/
- Ownership
- Privately Held (backing)
Nuritas doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuritas shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuritas in its N-PORT filings yet. We sweep new filings monthly.